285
Views
5
CrossRef citations to date
0
Altmetric
Review

Endogenous repair and development inspired therapy of neurodegeneration in progressive multiple sclerosis

, &
Pages 611-629 | Received 14 Jan 2016, Accepted 24 Jan 2017, Published online: 08 Feb 2017
 

ABSTRACT

Introduction: In recent years, there has been progress in understanding the etiology and immune mechanisms of multiple sclerosis (MS). however, for most, once the diagnosis is made, significant pathology is already present in the central nervous system (CNS), and in many, this leads to neurodegeneration, which accumulates in disability. although, the mechanisms of such progression are poorly understood, new data suggest lack of remyelination paired with dysfunction of neurons along with stem and progenitor cells as the basis and recent developmental studies suggest that cns repair processes share mechanisms with development.

Areas covered: Here, the authors examine the neurodevelopmental processes that may be reactivated to gain a better understanding of regeneration under pathological conditions. Specifically, the authors focus on the molecular framework of these mechanisms, signaling pathways in neuron and oligodendrocyte development, and provide evidence that the activation of these processes can help us design new therapeutic avenues to halt progression.

Expert commentary: Accumulating evidence indicates that there is no single mechanism of progression in MS; instead there is heterogeneity in which repair processes are perturbed. Together, this not only poses a challenge for treatment, but also at the benchside, when prioritizing which developmental targets warrant investigation in future trials.

Declaration of interest

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Additional information

Funding

This paper was not funded.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.